HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Yan Song(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhixiang Zhuang(Soochow University), Xiaoge Kou(First Affiliated Hospital of Xinxiang Medical University), Xiaofei Wang(Sichuan University), Ning Li(University of Science and Technology of China), Qun Li(Bristol-Myers Squibb (Germany)), Shu Zhang(Ministry of Education), Haijun Zhong(Zhejiang Cancer Hospital), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Xianli Yin(Central South University), Yunpeng Liu(Shenyang Institute of Automation), Xinjun Liang(Hubei Cancer Hospital), Yiwei Dou(New York University)
Cited by 20
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k